Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
Nyamankolly E, Bellecave P, Wittkop L, Le Marec F, Duffau P, Lazaro E, Vareil MO, Tumiotto C, Hessamfar M, Cazanave C, Perrier A, Leleux O, Bonnet F, Neau D. Nyamankolly E, et al. Among authors: bellecave p. Int J Antimicrob Agents. 2023 Jan;61(1):106696. doi: 10.1016/j.ijantimicag.2022.106696. Epub 2022 Dec 2. Int J Antimicrob Agents. 2023. PMID: 36470511
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P, Raymond S, Bellecave P, Marcelin AG, Soulie C, Descamps D, Calvez V, Harrigan PR, Fleury H, Izopet J, Masquelier B; S AC11 Resistance Study Group. Recordon-Pinson P, et al. Among authors: bellecave p. Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3. Antimicrob Agents Chemother. 2013. PMID: 23208718 Free PMC article.
Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.
Papuchon J, Pinson P, Guidicelli GL, Bellecave P, Thomas R, LeBlanc R, Reigadas S, Taupin JL, Baril JG, Routy JP, Wainberg M, Fleury H; Provir/Latitude 45 study group. Papuchon J, et al. Among authors: bellecave p. PLoS One. 2014 Jun 25;9(6):e100452. doi: 10.1371/journal.pone.0100452. eCollection 2014. PLoS One. 2014. PMID: 24964202 Free PMC article.
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group. Fourati S, et al. J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3. J Antimicrob Chemother. 2015. PMID: 25558077 Free article.
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chaix ML; AC43 ANRS Resistance Group. Visseaux B, et al. J Antimicrob Chemother. 2020 Jan 1;75(1):183-193. doi: 10.1093/jac/dkz404. J Antimicrob Chemother. 2020. PMID: 31641777
Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort.
Marcellin F, Miailhes P, Santos M, Mercié P, Di Beo V, Salmon-Céron D, Barré T, Wittkop L, Protopopescu C, Zucman D, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group. Marcellin F, et al. Clin Infect Dis. 2020 Dec 3;71(9):2536-2538. doi: 10.1093/cid/ciaa117. Clin Infect Dis. 2020. PMID: 32055846 No abstract available.
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
Marcelin AG, Charpentier C, Bellecave P, Abdi B, Chaix ML, Ferre V, Raymond S, Fofana D, Bocket L, Mirand A, Le Guillou-Guillemette H, Montes B, Amiel C, Pallier C, Fafi-Kremer S, De Monte A, Alessandri-Gradt E, Scholtes C, Maillard A, Jeulin H, Bouvier-Alias M, Roussel C, Dos Santos G, Signori-Schmuck A, Dina J, Vallet S, Stefic K, Soulié C, Calvez V, Descamps D, Flandre P; ANRS-MIE AC43 Group. Marcelin AG, et al. Among authors: bellecave p. J Antimicrob Chemother. 2021 Aug 12;76(9):2400-2406. doi: 10.1093/jac/dkab193. J Antimicrob Chemother. 2021. PMID: 34100068
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Lacombe JM, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH, ANRS CO22 HEPATHER Cohorts Study Groups; Martinez V. Chalouni M, et al. HIV Med. 2021 Nov;22(10):924-935. doi: 10.1111/hiv.13153. Epub 2021 Aug 17. HIV Med. 2021. PMID: 34402547 Free article.
67 results